Anthropic is launching its own drug discovery programs to tackle diseases that Big Pharma considers unprofitable, aiming to research treatments for neglected diseases and build better AI models. The company’s move aligns with its nonprofit mission and could help speed up medical research. Novartis CEO Vas Narasimhan notes that new AI models could cut drug development time and double success rates, which would have a huge impact when scaled across major pharma. Why it matters: this development could significantly accelerate the discovery of new treatments and make previously unprofitable diseases viable for research and treatment.